S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Options Trading Plan–Perfect For Beginners (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Options Trading Plan–Perfect For Beginners (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Options Trading Plan–Perfect For Beginners (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Options Trading Plan–Perfect For Beginners (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Options Trading Plan–Perfect For Beginners (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Options Trading Plan–Perfect For Beginners (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Forecast, Price & News

$2.76
-0.08 (-2.82%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.76
$3.00
50-Day Range
$2.76
$11.85
52-Week Range
$2.76
$34.13
Volume
497,073 shs
Average Volume
1.39 million shs
Market Capitalization
$80.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.88

BioXcel Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
765.0% Upside
$23.88 Price Target
Short Interest
Healthy
21.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.75) to ($2.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

117th out of 964 stocks

Pharmaceutical Preparations Industry

35th out of 441 stocks


BTAI stock logo

About BioXcel Therapeutics (NASDAQ:BTAI) Stock

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Price History

BTAI Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
H.C. Wainwright Keeps Their Buy Rating on Bioxcel Therapeutics (BTAI)
BioXcel Therapeutics (NASDAQ: BTAI)
BTAI: Strategic Reprioritization Underway...
Why BioXcel Therapeutics Stock Flopped Again Today
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
183
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$23.88
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+765.0%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-165,760,000.00
Net Margins
-19,549.52%
Pretax Margin
-19,549.71%

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$2.74 per share

Miscellaneous

Free Float
18,791,000
Market Cap
$80.79 million
Optionable
Not Optionable
Beta
1.00

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 62)
    Founder, CEO, Pres, & Director
    Comp: $1.76M
  • Mr. Javier Rodriguez (Age 51)
    Sr. VP, Chief Legal Officer & Corp. Sec.
    Comp: $638.88k
  • Mr. Matthew Wiley (Age 51)
    Sr. VP & Chief Commercial Officer
    Comp: $620.12k
  • Mr. Richard I. Steinhart MBA (Age 66)
    Sr. VP & CFO
  • Dr. Frank D. Yocca Ph.D. (Age 67)
    Sr. VP & Chief Scientific Officer
  • Dr. Vincent J. O'Neill B.Sc. (Age 54)
    M.D., M.R.C.P., Sr. VP & Chief Medical Officer
  • Dr. Chetan D. Lathia Ph.D.
    Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
  • Dr. Robert Risinger M.D.
    Chief Medical Officer - Neuroscience
  • Mr. Robert Scala (Age 54)
    VP of Commercial Operations & Launch Planning
  • Dr. Friso Postma
    Sr. Director of Neuroscience & Artificial intelligence













BTAI Stock - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price forecast for 2023?

7 Wall Street research analysts have issued 12-month price targets for BioXcel Therapeutics' stock. Their BTAI share price forecasts range from $11.00 to $40.00. On average, they predict the company's share price to reach $23.88 in the next year. This suggests a possible upside of 765.0% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2023?

BioXcel Therapeutics' stock was trading at $21.48 at the beginning of the year. Since then, BTAI shares have decreased by 87.2% and is now trading at $2.76.
View the best growth stocks for 2023 here
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Monday, August, 14th. The company reported ($1.83) EPS for the quarter, missing the consensus estimate of ($1.72) by $0.11. The business earned $0.46 million during the quarter, compared to analyst estimates of $0.42 million. BioXcel Therapeutics had a negative net margin of 19,549.52% and a negative trailing twelve-month return on equity of 309.06%. The business's revenue was up 45600.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.35) earnings per share.

What ETF holds BioXcel Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (7.11%), BlackRock Inc. (4.76%), Artemis Investment Management LLP (3.07%), Geode Capital Management LLC (1.39%), Northern Trust Corp (0.84%) and Point72 Asset Management L.P. (0.83%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill.
View institutional ownership trends
.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $2.76.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $80.79 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($7.11) on an earnings per share basis.

How many employees does BioXcel Therapeutics have?

The company employs 183 workers across the globe.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.

This page (NASDAQ:BTAI) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -